Open access
Aug 2026
T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1
Bispecific antibodies have gradually been applied in the treatment of multiple myeloma(MM). The combination of bispecific antibodies targeting CD3 and CD28 mimics the dual-signaling system (antigen signaling and co-stimulatory signaling) of natural T cell activation, thereby significantly enhancing the anti-tumor res...
Chaofan Wang, Wanting Wang, Mo-Ran Wang et al.
· Cell Death & Disease · 0 citations